Evaluating the Content Validity, Clarity, and Relevance of Two Patient-Reported Outcomes for Use With Adults With EGFR-Mutated NSCLC

Evaluating the Content Validity, Clarity, and Relevance of Two Patient-Reported Outcomes for Use With Adults With EGFR-Mutated NSCLC

Introduction: NSCLCs account for most lung cancers; approximately 30% involve a mutation in the EGFR gene. This study sought to identify one or more patient-reported outcome (PRO) measures relevant for use in clinical trials to assess symptoms and health-related quality of life in this population. M...

Full description

Bibliographic Details
Main Authors:	Marcia K. Horn, JD, Kevin Liu, PharmD, Susan D. Mathias, MPH, Hilary H. Colwell, MPH, Tracy Li, PhD, Parthiv Mahadevia, MD, Renee F. Pierson, MBA
Format:	Article
Language:	English
Published:	Elsevier 2021-08-01
Series:	JTO Clinical and Research Reports
Subjects:	Non-small cell lung cancer Patient-reported outcomes Exon 20 insertion mutation Epidermal growth factor receptor
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364321000576

Similar Items

Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer
by: Wensheng ZHOU, et al.
Published: (2020-02-01)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
by: Lin L, et al.
Published: (2020-09-01)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
by: Zhang SS, et al.
Published: (2021-07-01)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
by: Sabine Zöchbauer-Müller, et al.
Published: (2021-01-01)

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
by: Hou H, et al.
Published: (2019-06-01)

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
by: Pedro E.N.S. Vasconcelos, MS, et al.
Published: (2021-03-01)

Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
by: YanRu Qin, et al.
Published: (2020-08-01)

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
by: Pacini L, et al.
Published: (2021-03-01)

High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
by: de Langen, A.J, et al.
Published: (2022)

PI3K pathway in NSCLC
by: Alex eMartínez Martí, et al.
Published: (2012-01-01)

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
by: Chen D, et al.
Published: (2016-07-01)

Detection of rare targetable EGFR variant in Metastatic Non-small Cell Lung Carcinoma by next Generation Sequencing: A Case Report
by: Anurag Mehta, et al.
Published: (2020-06-01)

Immunohistochemical Detections of EGFR Mutations in NSCLC
by: Chang LIU, et al.
Published: (2014-09-01)

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
by: Pedro E.N.S. Vasconcelos, MS, et al.
Published: (2020-09-01)

Immunohistochemical detections of EGFR status in NSCLC
by: Jie WANG, et al.
Published: (2015-04-01)

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
by: Alessandro Russo, et al.
Published: (2019-03-01)

Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment
by: Noronha V, et al.
Published: (2017-06-01)

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
by: Kiichiro Ninomiya, MD, PhD, et al.
Published: (2021-01-01)

Expression and its Clinical Significance of NOK, EGFR in NSCLC
by: Zhipei ZHANG, et al.
Published: (2009-09-01)

Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations
by: Mahlet Z. Tamirat, et al.
Published: (2021-03-01)

Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib
by: Bo Yuan, et al.
Published: (2020-05-01)

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
by: Amit Joshi, et al.
Published: (2018-01-01)

Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers
by: Vidhi Malik, et al.
Published: (2021-01-01)

THE PHARMACOGENOMICS OF EGFR-DEPENDENT NSCLC: PREDICTING AND ENHANCING RESPONSE TO TARGETED EGFR THERAPY
by: Balko, Justin M.
Published: (2009)

Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy
by: Leanne G. Ahronian, et al.
Published: (2017-04-01)

USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells
by: Aidan P. McCann, et al.
Published: (2018-11-01)

Successful Resection of G719X-Positive Pleomorphic Carcinoma after Afatinib Treatment
by: Daisuke Nakamura, et al.
Published: (2017-11-01)

Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report
by: Shun Matsuura, et al.
Published: (2020-01-01)

Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy  in Advanced NSCLC Patients with EGFR Mutations
by: Minjiang CHEN, et al.
Published: (2019-02-01)

Osimertinib Did Not Respond to a Pulmonary Adenocarcinoma with Triple Mutations of Epidermal Growth Factor Receptor, G719S, T790M and S768I
by: Seigo Minami, et al.
Published: (2019-02-01)

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
by: Jiang-Yong Yu, et al.
Published: (2016-03-01)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01)

Expressions of c-Cbl, Cbl-b and EGFR and Its Role of Prognosis in NSCLC
by: Xin JIAO, et al.
Published: (2011-06-01)

Mutations in the exons of epidermal growth factor receptor gene are associated with clinicopathological features of lung cancer
by: Yanhui Wan, et al.
Published: (2020-10-01)

Morphological, immunohistochemical, and genetic analyses of bronchiolar adenoma and its putative variants
by: Jinchen Shao, et al.
Published: (2021-05-01)

Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated NSCLC patients who develop brain metastasis
by: Wenxian Wang, et al.
Published: (2018-10-01)

How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?
by: Chuanhao TANG, et al.
Published: (2013-07-01)

Treatment for Brain Metastases from EGFR Mutations NSCLC Patients: How Should We Choose in Clinical Practice?
by: Cheng CHENG, et al.
Published: (2020-08-01)

The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
by: Chutong Lin, et al.
Published: (2021-04-01)

Evaluation of EGFR mutation status by radiographic characteristics of MRI in NSCLC patients with brain metastasis
by: HE Rong, et al.
Published: (2019-03-01)